



Curriculum vitae

Name Michael Fuchs



Contact data

Address Burg 20, 51491 Overath, Germany

Telephone (home) +49 2206 8 529 329

Mobile +49 179 4974857

E-mail fuchs.koeln@web.de

Personal data

Nationality German

Age 50 years

Place of birth Cologne, Germany

Professional experience

Since 01.06.2012 Expertise Auditor for Trial Centers, Certification Board Trial Centers of the DGHO

Since 01.01.2008 Head of the GHSG Trial Coordination Center

Since 01.01.2005 Study physician at the German Hodgkin Study Group (GHSG)

Since 01.01.2000 Assistant physician at the Clinic for Internal Medicine of the Cologne University Hospital; worked in the departments for haematology, oncology and bone marrow transplantation (main areas of expertise), as well as in the departments for intensive care, cardiology and gastro-enterology (as part of the specialist training in internal medicine)

1998 – 1999 Junior house officer in the department for bone marrow transplantation of the Cologne University Hospital

1998 Scientific assistant at the laboratory of the department for bone marrow transplantation of the Cologne University Hospital

1997/98 Final year student, 4 months practical training at Canton Hospital of Aarau, Switzerland, department for anaesthesia

1996 – 1998 Student assistant at the laboratory of the department for bone marrow transplantation of the Cologne University Hospital





1993 – 1997

Freelance assistant at Cologne based TV and radio station (WDR); organisation and production of radio publications

Studies / Education

1998

Third medical state examination / licence to practise medicine

1991 – 1998

Medical studies at the University of Cologne

1982 – 1991

Grammar school, Cologne

Graduation: Abitur (\approx A-levels)

1978 – 1982

Primary school, Cologne

Special skills / further training (in extracts)

2009, Cologne, Germany

Training course: The role of an investigator in clinical trials (Prüfarztkurs)

2009, Frankfurt, Germany

Training course: DIN ISO 9001:2008

2008, Vienna, Austria

Training course: GCP for non-commercial clinical trial in haematology and oncology, legal regulations, ICH-GCP, quality standards, background and implementation

2007, Basle, Switzerland

Training course: GCP for non-commercial clinical trial in haematology and oncology, legal regulations, ICH-GCP, quality standards, background and implementation

2006, Cologne, Germany

Training course: Principle investigator in clinical trials (Studienleiter-Kurs)

2005, Düsseldorf, Germany

Training course: The role of an investigator in clinical trials (Prüfarztkurs)

2005, Krefeld, Germany

Training course: Working as a physician in emergency ambulance service

2004, Altleiningen, Germany

Training course: Clinical infectiology in haematology and oncology

2001, Eschweiler, Germany

Training course: Haematologic cytology

1999, Flims, Switzerland

Workshop: "Methods in Clinical Cancer Research"

English language skills

Fluent in spoken and written



**Computer skills**

Very good (Word, Excel, Office applications, File-Maker, Endnote)

Memberships

Deutsche Gesellschaft für Hämatologie und Internistische
Onkologie (DGHO)

European Hematology Association (EHA)

Marburger Bund

Clinical Trials (in extracts)

2008	SI, WC	HD18 für fortgeschrittene Stadien: Therapieoptimierungsstudie in der Primärtherapie des fortgeschrittenen Hodgkin Lymphoms EudraCT: 2007-003187-22
2009	SI, WC	HD16 für frühe Stadien: Therapieoptimierungsstudie in der Primärtherapie des frühen Hodgkin Lymphoms EudraCT: 2007-004474-24
2009	SI	A phase 2 study of SGN-35 in treatment of patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL) EudraCT: 2008-006035-12
2010	SI	AVD-Rev in elderly Hodgkin Lymphoma patients Phase I trial of AVD plus Lenalidomide in elderly intermediate or advanced stage Hodgkin Lymphoma patients EudraCT: 2008-008737-11
2010	SI	An intensive QT/QTc study to investigate the effects of SGN-35 on cardiac ventricular repolarisation in patients with CD30-positive malignancies EudraCT: 2009-017128-21
2010	SI	A pharmacodynamically-guided dose escalation phase I study to assess the safety of AFM13 (recombinant antibody construct against human CD30 and CD16A) in patients with refractory and/or relapsed Hodgkin's lymphoma EudraCT: 2010-019232-13
2010	SI	A Phase III randomized, double blind, placebo controlled multi-center study of panobinostat for maintenance of response in patients with Hodgkin's lymphoma who are at risk for relapse after high dose chemotherapy and autologous stem cell transplant EudraCT: 2009-014846-26





2012 SI

A prospective, randomized, placebo-controlled, international, multicenter phase I/II trial of RAD001 (everolimus) in combination with DHAP as induction therapy in patients with relapsed or refractory Hodgkin Lymphoma

EudraCT: 2010-021086736

DRC: Data Review Committee

DSMB: Data Safety Monitoring Board

LKP: Leiter klinische Prüfung (gem. Arzneimittelgesetz)

PI: Principle Investigator

PSC: Protocol Steering Committee

SI: Subinvestigator

WC: Writing Committee

Last updated: 20.03.2023

